Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M146,678Revenue $M14,424Net Margin (%)31.5Altman Z-Score17.7
Enterprise Value $M145,721EPS $1.8Operating Margin %42.1Piotroski F-Score8
P/E(ttm)30.6Beneish M-Score-2.8Pre-tax Margin (%)40.2Higher ROA y-yY
Price/Book24.210-y EBITDA Growth Rate %18.8Quick Ratio0.9Cash flow > EarningsY
Price/Sales9.65-y EBITDA Growth Rate %19.6Current Ratio1.2Lower Leverage y-yY
Price/Free Cash Flow30.9y-y EBITDA Growth Rate %29.2ROA % (ttm)42.1Higher Current Ratio y-yN
Dividend Yield %1.3PEG1.6ROE % (ttm)83.9Less Shares Outstanding y-yY
Payout Ratio %42.0Shares Outstanding M2,650ROIC % (ttm)122Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVOKen Fisher 2015-06-30 Reduce-0.04%$53.39 - $58.02
($56.17)
$ 55.35-1%Reduce 2.88%12,295,864
NVORuane Cunniff 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 55.35-1%Reduce 0.30%81,800
NVOMario Gabelli 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 55.35-1%Reduce 2.31%6,545
NVOKen Fisher 2015-03-31 Reduce-0.03%$41.9 - $54.68
($46.05)
$ 55.3520%Reduce 2.91%12,660,235
NVORuane Cunniff 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 55.3520%Reduce 0.17%82,050
NVOMario Gabelli 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 55.3520%Reduce 0.30%6,700
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 55.3520%Reduce 52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 55.3525%Reduce 33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 55.3531%Reduce 21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.952
($34.87)
$ 55.3559%Add 58.71%310,970
NVOTom Gayner 2013-12-31 Reduce$32.72 - $36.952
($34.87)
$ 55.3559%Reduce 0.23%1,106,000
NVOKen Fisher 2013-12-31 Add$32.72 - $36.952
($34.87)
$ 55.3559%Add 0.29%13,553,935
NVOTom Gayner 2013-09-30 Reduce-0.02%$31.67 - $35.236
($33.64)
$ 55.3565%Reduce 1.51%1,108,500
NVOKen Fisher 2013-09-30 Add$31.67 - $35.236
($33.64)
$ 55.3565%Add 0.43%13,514,205
NVORuane Cunniff 2013-09-30 Add$31.67 - $35.236
($33.64)
$ 55.3565%Add 13.12%195,930
NVOMario Gabelli 2013-09-30 Reduce$31.67 - $35.236
($33.64)
$ 55.3565%Reduce 0.58%8,520
NVORuane Cunniff 2013-06-30 Buy 0.04%$30.11 - $35.326
($33.29)
$ 55.3566%New holding173,200
NVOTom Gayner 2013-06-30 Reduce-0.01%$30.11 - $35.326
($33.29)
$ 55.3566%Reduce 0.57%1,125,500
NVOKen Fisher 2013-06-30 Add0.01%$30.11 - $35.326
($33.29)
$ 55.3566%Add 0.92%13,456,455
NVOMario Gabelli 2013-06-30 Reduce$30.11 - $35.326
($33.29)
$ 55.3566%Reduce 1.15%8,570
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about NVO:

    News about NVO:

    Articles On GuruFocus.com
    Nintai Returns: Q2 2015 Jul 01 2015 
    Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
    Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
    Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
    MannKind Looks Good For Long Term Investors Apr 29 2015 
    Additional Changes to the Nintai Portfolio Apr 08 2015 
    Probability and Magnitude in Investing Apr 02 2015 
    Nintai Returns: Q1 2015 Apr 01 2015 
    These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
    To Reinvest or Not Reinvest: That is the Question Feb 19 2015 

    More From Other Websites
    Is Novo Nordisk (NVO) an Incredible Growth Stock? 3 Reasons Why It Will Be Tough to Beat Aug 31 2015
    Now the work starts for Novo Nordisk in Clayton Aug 28 2015
    Research and Markets: China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk Aug 28 2015
    Coverage initiated on Novo Nordisk A/S by Leerink Partners Aug 28 2015
    Novo Nordisk to Start PIONEER Program on Semaglutide Aug 27 2015
    Effective obesity management: It's more than reducing numbers on the scale Aug 27 2015
    Effective obesity management: It's more than reducing numbers on the scale Aug 27 2015
    Novo Nordisk adding diabetes drug output in NC, Denmark Aug 26 2015
    Novo Nordisk adding diabetes drug output in NC, Denmark Aug 26 2015
    Nearly 700 N.C. jobs announced as part of $1.2B Novo Nordisk expansion Aug 26 2015
    Emisphere Highlights Eligen Licensee Novo Nordisk's Entry Into Phase 3a Development of Oral... Aug 26 2015
    Emisphere Highlights Eligen Licensee Novo Nordisk's Entry Into Phase 3a Development of Oral... Aug 26 2015
    Novo Nordisk A/S Q2 Earnings Analysis: By the Numbers, 2015 Aug 24 2015
    Novo May Benefit From Possible Shire-Baxalta Disruption Aug 14 2015
    Biggest Insulin Maker May Build Next Diabetes Drug Plant in U.S. Aug 14 2015
    Moody's: Accelerated growth expected for EMEA Pharmaceuticals in 2016 Aug 11 2015
    Novo Nordisk's Net Income Up Y/Y, 2015 Outlook Maintained - Analyst Blog Aug 07 2015
    We want to be seen as Chinese: Novo Nordisk Aug 06 2015
    China gets tougher for Western drugmakers Aug 06 2015
    Research and Markets: Investigation Report on China's Liraglutide Market, 2011-2019 Featuring Novo... Aug 06 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    Gintaras58
    ReplyGintaras58 - 1 year ago
    few excellent prducts to come soon
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK